カテゴリ： GlobalData, アメリカ, 企業調査

Blueprint Medicines Corp (BPMC)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Blueprint Medicines Corp (BPMC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8214
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：81
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is a drug discovery company that develops drugs for the treatment of cancers and rare diseases. The company discovers and develops selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-554, used in advanced hepatocellular carcinoma; avapritinib, used in the treatment for unresectable, treatment-resistant gastrointestinal stromal tumors and advanced systemic mastocytosis; and BLU-667, for ret-mutations, fusions, and predicted resistant mutants. Its preclinical product candidate BLU-782 is intended for ALK2 mutations in fibrodysplasia ossificans progressiva. The company also discovers product candidates for kinase targets and immunokinase targets. The company operates through genomic and cancer research institutions located in the US. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

Blueprint Medicines Corp (BPMC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Blueprint Medicines Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Blueprint Medicines Raises USD50 Million in Series C Venture Financing 13
Blueprint Medicines Raises US$25 Million In Series B Venture Financing 16
Blueprint Medicines Raises US$40 Million In Series A Venture Financing 18
Partnerships 20
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 20
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 21
Licensing Agreements 22
CStone Pharma Enters into Licensing Agreement with Blueprint Medicines 22
Roche Enters into Licensing Agreement with Blueprint Medicines 24
Equity Offering 26
Blueprint Medicines Raises USD325.5 Million in Public Offering of Shares 26
Blueprint Medicines Raises USD230 Million in Public Offering of Shares 28
Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 30
Blueprint Medicines Completes IPO 32
Blueprint Medicines Corp – Key Competitors 34
Blueprint Medicines Corp – Key Employees 35
Blueprint Medicines Corp – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 01, 2018: Blueprint medicines reports second quarter 2018 financial results 37
May 02, 2018: Blueprint Medicines Reports First Quarter 2018 Financial Results 39
Feb 21, 2018: Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results 41
Oct 31, 2017: Blueprint Medicines Reports Third Quarter 2017 Financial Results 43
Aug 02, 2017: Blueprint Medicines Reports Second Quarter 2017 Financial Results 45
May 03, 2017: Blueprint Medicines Reports First Quarter 2017 Financial Results 46
Mar 09, 2017: Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results 48
Research And Development 50
Jul 27, 2017: Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion 50
Corporate Communications 51
Oct 10, 2017: Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations 51
Product News 52
04/15/2018: Selective Inhibitor Shows Early Promise in Patients With RET-altered Cancers 52
03/27/2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences 53
03/27/2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences 54
Clinical Trials 55
Jun 21, 2018: Blueprint doses first patient in Voyager trial 55
Jun 15, 2018: Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity 56
May 17, 2018: Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis 59
Apr 15, 2018: Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors 60
Apr 15, 2018: Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 62
Mar 14, 2018: Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018 63
Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity 64
Dec 10, 2017: Blueprint Medicines: Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder 66
Nov 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR alpha Genotypes 67
Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data 70
Nov 01, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition 71
Sep 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma 72
Aug 21, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference 74
Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 75
Aug 02, 2017: Blueprint Medicines Provides Update on Hepatocellular Carcinoma Drug BLU-554 76
Jun 05, 2017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation 77
May 17, 2017: Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting 79
Mar 20, 2017: Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List of Tables
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Blueprint Medicines Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Blueprint Medicines Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Blueprint Medicines Raises USD50 Million in Series C Venture Financing 13
Blueprint Medicines Raises US$25 Million In Series B Venture Financing 16
Blueprint Medicines Raises US$40 Million In Series A Venture Financing 18
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 20
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 21
CStone Pharma Enters into Licensing Agreement with Blueprint Medicines 22
Roche Enters into Licensing Agreement with Blueprint Medicines 24
Blueprint Medicines Raises USD325.5 Million in Public Offering of Shares 26
Blueprint Medicines Raises USD230 Million in Public Offering of Shares 28
Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 30
Blueprint Medicines Completes IPO 32
Blueprint Medicines Corp, Key Competitors 34
Blueprint Medicines Corp, Key Employees 35
Blueprint Medicines Corp, Subsidiaries 36

List of Figures
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Blueprint Medicines Corp (BPMC)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hindustan ZInc Ltd：戦略・SWOT・企業財務分析
    Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MILEI GmbH：戦略・SWOT・企業財務分析
    MILEI GmbH - Strategy, SWOT and Corporate Finance Report Summary MILEI GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Sun Pharma Advanced Research Company Ltd (SPARC)：製薬・医療：M&Aディール及び事業提携情報
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • Aker Solutions ASA (AKSO)：石油・ガス：M&Aディール及び事業提携情報
    Summary Aker Solutions ASA (Aker Solutions) is a global provider of engineering, design, production systems and services to the oil and gas industry. The company offers subsea production equipment and offshore field design, ranging from concept studies and front-end engineering to subsea production …
  • Prismic Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Prismic Pharmaceuticals Inc (Prismic Pharmaceuticals) is a specialty pharmaceutical company that offers development of prescription drugs. The company offers research and development programs for prescription product candidates and provides unique safety profiles. It develops drugs for infla …
  • Heidelberg Pharma AG (HPHA)：企業の財務・戦略的SWOT分析
    Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • First Derivatives plc (FDP)：企業の財務・戦略的SWOT分析
    First Derivatives plc (FDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • GenomicTree Inc：企業の製品パイプライン分析2018
    Summary GenomicTree Inc (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung and …
  • Landesbank Berlin Holding AG：企業の戦略・SWOT・財務情報
    Landesbank Berlin Holding AG - Strategy, SWOT and Corporate Finance Report Summary Landesbank Berlin Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Tetra Pak International SA：企業の戦略的SWOT分析
    Tetra Pak International SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Theratechnologies Inc (TH)：製薬・医療：M&Aディール及び事業提携情報
    Summary Theratechnologies Inc (Theratechnologies) is a pharmaceutical company that focuses on the discovery and development of drugs for metabolic disorders. The company develops therapeutic peptide products, with an emphasis on growth releasing factor (GRF) peptides. Its lead products include Egrif …
  • Beth Israel Deaconess Medical Center Inc-製薬・医療分野：企業M&A・提携分析
    Summary Beth Israel Deaconess Medical Center Inc (BIDMC), a subsidiary of CareGroup Inc is a healthcare center that offers clinical care, biomedical research and education, health and wellness services. The center offers patient and family care services such as admitting, case management, ethics sup …
  • Tainergy Tech Co Ltd (4934)：電力：M&Aディール及び事業提携情報
    Summary Tainergy Tech Co Ltd (Tainergy) is a renewable energy company that designs, develops, manufactures and markets solar energy products. The company provides products such as solar deionized water systems, multi-crystalline silicon solar cell, standard solar modules, solar module with build in …
  • Oxurion NV (OXUR)：企業の財務・戦略的SWOT分析
    Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Croda International Plc (CRDA)：企業の財務・戦略的SWOT分析
    Croda International Plc (CRDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Energy Focus, Inc. (EFOI)-エネルギー分野：企業M&A・提携分析
    Summary Energy Focus, Inc. (Energy Focus) is a provider of energy efficient LED lighting products and technologies. The company, together with its subsidiaries, designs, develops, manufactures, markets, and installs energy-efficient lighting systems and solutions. Its military maritime products incl …
  • MicroPort Scientific Corp (853)：医療機器：M&Aディール及び事業提携情報
    Summary MicroPort Scientific Corp (MicroPort) a subsidiary of Otsuka Medical Devices Co Ltd is a medical device company which develops, manufactures and markets cardiovascular treatment devices. The company provides products such as cardiovascular devices, orthopedic devices, endovascular devices, e …
  • HUYA Bioscience International LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary HUYA Bioscience International LLC (HUYA) is a biopharmaceutical company that develops early and late-stage drug candidates. The company’s pipeline products include HBI-8000, HBI-3000, and HBI-3802. Its HBI-8000 is a novel oral inhibitor of histone deacetylases; HBI-3000 is a channel blocker …
  • Samart Corporation Public Co Ltd (SAMART)：企業の財務・戦略的SWOT分析
    Samart Corporation Public Co Ltd (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Catholic United Financial：企業の戦略的SWOT分析
    Catholic United Financial - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆